Access to Medicine Index+Access to Medicine Overall Score
2

Access to Medicine Overall Score

How did the company score in the Access to Medicine Index?

Company
Industry
Project
search
Year
Metric value
Companies Values
GlaxoSmithKline
2014 = 3.3 /0-5
Novo Nordisk
2014 = 3 /0-5
Merck KGaA
2014 = 2.8 /0-5
Johnson&Johnson
2014 = 2.8 /0-5
Gilead Sciences
2014 = 2.8 /0-5
Novartis
2014 = 2.8 /0-5
AbbVie Inc.
2014 = 2.6 /0-5
Sanofi
2014 = 2.6 /0-5
Merck & Co
2014 = 2.6 /0-5
Bayer AG
2014 = 2.5 /0-5
Eisai
2014 = 2.5 /0-5
Roche Holding
2014 = 2.3 /0-5
Pfizer
2014 = 1.9 /0-5
AstraZeneca
2014 = 1.9 /0-5
Eli Lilly & Co
2014 = 1.7 /0-5
Astellas Pharma
2014 = 1.6 /0-5
Daiichi Sankyo
2014 = 1.5 /0-5
Takeda Pharmaceutical
2014 = 1.5 /0-5
Alpina Foods
2015 = Unknown /0-5
Oriflame Cosmetics AB
2018 = Unknown /0-5

Export: csv / json

Designed By
Topics
Metric Type
Researched
Research Policy
Designer Assessed
Report Type
Value Type
Number
Unit:
Range:
0-5

About

The Access to Medicine Index gives insight into what the pharmaceutical industry is doing to improve access to medicine across the world. It independently ranks and evaluates the world's largest pharmaceutical companies on their policies and practices for improving access to medicine in developing countries and has been published every two years since 2008. 

20 companies were analysed by the 2014 Index which together accounts for more than 50% of the global pharmaceutical market.

More detailed information is available here: http://www.accesstomedicineindex.org/ranking

Methodology

The framework is constructed along seven areas of focus, which cover the range of company business activities that experts consider most relevant to access to medicine. Within each area, the Index assesses four aspects of company action: commitment, transparency, performance and innovation. In 2014 there were 95 indicators.

The Index is a relative ranking, where companies are compared with each other rather than against an absolute. The highest attainable scores for each indicator do not reflect an ideal characteristic of industry behaviour, but a culmination of stakeholder views of what can be reasonably expected of companies. Additionally, companies do not receive negative scores in indicators, meaning they can never score below zero.

More detailed methodology is available here: http://www.accesstomedicineindex.org/methodology-0

Bulk Import